Guardant Health, a Redwood City, Calif.-based developer of diagnostic technologies, completed its $50m Series C financing.
The funding was led by Lightspeed Venture Partners with participation from Formation 8 and existing investors Khosla Ventures and Sequoia Capital.
The company, which has raised under $100 million in total, plans to use the funds to expand the availability of Guardant360, and continue to invest in the acceleration of its product roadmap.
Led by Helmy Eltoukhy, CEO, Guardant provides Guardant360, a comprehensive biopsy-free cancer test that identifies critical tumor genomic alterations in real-time.
The company also announced enhancements to its Guardant360 cancer blood test by increasing the number of clinically relevant genes and the types of alterations tested. The 68 gene panel now includes all NCCN recommended genomic biomarkers, including clinically relevant gene mutations, insertions/deletions, amplifications and fusions.